These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 2891816)

  • 1. Crystallographic, theoretical and molecular modelling studies on the conformations of the salicylamide, raclopride, a selective dopamine-D2 antagonist.
    Högberg T; Norinder U; Rämsby S; Stensland B
    J Pharm Pharmacol; 1987 Oct; 39(10):787-96. PubMed ID: 2891816
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Solid state conformations and antidopaminergic effects of remoxipride hydrochloride and a closely related salicylamide, FLA 797, in relation to dopamine receptor models.
    Högberg T; Rämsby S; de Paulis T; Stensland B; Csöregh I; Wägner A
    Mol Pharmacol; 1986 Oct; 30(4):345-51. PubMed ID: 2945089
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potential antipsychotic agents. 9. Synthesis and stereoselective dopamine D-2 receptor blockade of a potent class of substituted (R)-N-[(1-benzyl-2-pyrrolidinyl)methyl]benzamides. Relations to other side chain congeners.
    Högberg T; Ström P; de Paulis T; Stensland B; Csöregh I; Lundin K; Hall H; Ogren SO
    J Med Chem; 1991 Mar; 34(3):948-55. PubMed ID: 1672158
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The development of dopamine D2-receptor selective antagonists.
    Högberg T
    Drug Des Discov; 1993; 9(3-4):333-50. PubMed ID: 8400011
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MK-801-induced hyperlocomotion: differential effects of M100907, SDZ PSD 958 and raclopride.
    Martin P; Waters N; Waters S; Carlsson A; Carlsson ML
    Eur J Pharmacol; 1997 Sep; 335(2-3):107-16. PubMed ID: 9369362
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular structure and absolute configuration of the hydrochloride of a novel dopamine receptor antagonist: 2S(-)-5-chloro-3-ethyl-N-[(1-ethyl-2-pyrrolidinyl) methyl]-6-methoxysalicylamide.
    Wägner A; Stensland B; Csöregh I; de Paulis T
    Acta Pharm Suec; 1985; 22(2):101-10. PubMed ID: 4050456
    [No Abstract]   [Full Text] [Related]  

  • 7. Syntheses of [123I]-, [125I]- and unlabelled (S)-3-iodo-5,6-dimethoxy-N-[(1-ethyl-2-pyrrolidinyl)methyl]salicylamide (NCQ 298), selective ligands for the study of dopamine D-2 receptors.
    Högberg T; Ström P; Hall H; Köhler C; Halldin C; Farde L
    Acta Pharm Nord; 1990; 2(1):53-60. PubMed ID: 1971177
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stereoelectronic study of zetidoline, a dopamine D2 receptor antagonist.
    Collin S; Evrard G; Vercauteren DP; Durant F; Carrupt PA; van de Waterbeemd H; Testa B
    J Med Chem; 1989 Jan; 32(1):38-42. PubMed ID: 2521253
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Remoxipride shows low propensity to block functional striatal dopamine D2 receptors in vitro.
    Westlind-Danielsson A; Gustafsson K; Andersson I
    Eur J Pharmacol; 1994 Dec; 288(1):89-95. PubMed ID: 7705472
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potential neuroleptic agents. 4. Chemistry, behavioral pharmacology, and inhibition of [3H]spiperone binding of 3,5-disubstituted N-[(1-ethyl-2-pyrrolidinyl)methyl]-6-methoxysalicylamides.
    de Paulis T; Kumar Y; Johansson L; Rämsby S; Hall H; Sällemark M; Angeby-Möller K; Ogren SO
    J Med Chem; 1986 Jan; 29(1):61-9. PubMed ID: 3941414
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Specific in vitro and in vivo binding of 3H-raclopride. A potent substituted benzamide drug with high affinity for dopamine D-2 receptors in the rat brain.
    Köhler C; Hall H; Ogren SO; Gawell L
    Biochem Pharmacol; 1985 Jul; 34(13):2251-9. PubMed ID: 4015674
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and binding properties of the fluorinated substituted benzamide [3H]NCQ 115, a new selective dopamine D2 receptor ligand.
    Hall H; Högberg T; Halldin C; Bengtsson S; Wedel I
    Eur J Pharmacol; 1991 Aug; 201(1):1-10. PubMed ID: 1686586
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potential antipsychotic agents. 7. Synthesis and antidopaminergic properties of the atypical highly potent (S)-5-bromo-2,3-dimethoxy-N-[(1-ethyl-2-pyrrolidinyl)methyl]benzamide and related compounds. A comparative study.
    Högberg T; de Paulis T; Johansson L; Kumar Y; Hall H; Ogren SO
    J Med Chem; 1990 Aug; 33(8):2305-9. PubMed ID: 1973734
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the pharmacological characteristics of [3H]raclopride and [3H]SCH 23390 binding to dopamine receptors in vivo in mouse brain.
    Andersen PH
    Eur J Pharmacol; 1988 Jan; 146(1):113-20. PubMed ID: 2895008
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Autoradiographic visualization of dopamine D-2 receptors in the monkey brain using the selective benzamide drug [3H]raclopride.
    Köhler C; Radesäter AC
    Neurosci Lett; 1986 May; 66(1):85-90. PubMed ID: 2940480
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Animal pharmacology of raclopride, a selective dopamine D2 antagonist.
    Hall H; Ogren SO; Köhler C; Magnusson O
    Psychopharmacol Ser; 1989; 7():123-30. PubMed ID: 2687851
    [No Abstract]   [Full Text] [Related]  

  • 17. Selective unilateral inactivation of striatal D1 and D2 dopamine receptor subtypes by EEDQ: turning behavior elicited by D2 dopamine receptor agonists.
    Giorgi O; Biggio G
    Brain Res; 1990 Nov; 533(1):53-9. PubMed ID: 1982234
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of monovalent cations on neostriatal dopamine D2 receptors labeled with [3H]raclopride.
    Reader TA; Boulianne S; Molina-Holgado E; Dewar KM
    Biochem Pharmacol; 1990 Oct; 40(8):1739-46. PubMed ID: 2146961
    [TBL] [Abstract][Full Text] [Related]  

  • 19. S 18126 ([2-[4-(2,3-dihydrobenzo[1,4]dioxin-6-yl)piperazin-1-yl methyl]indan-2-yl]), a potent, selective and competitive antagonist at dopamine D4 receptors: an in vitro and in vivo comparison with L 745,870 (3-(4-[4-chlorophenyl]piperazin-1-yl)methyl-1H-pyrrolo[2, 3b]pyridine) and raclopride.
    Millan MJ; Newman-Tancredi A; Brocco M; Gobert A; Lejeune F; Audinot V; Rivet JM; Schreiber R; Dekeyne A; Spedding M; Nicolas JP; Peglion JL
    J Pharmacol Exp Ther; 1998 Oct; 287(1):167-86. PubMed ID: 9765336
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dopamine receptor antagonists block nerve growth factor-induced hyperactivity.
    Kobayashi S; Ogren SO; Ebendal T; Olson L
    Eur J Pharmacol; 1997 May; 326(1):1-5. PubMed ID: 9178648
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.